Tatsuro Yokoyama

This inventor holds 11 USPTO granted patents. Top assignees: Mitsui Toatsu Chemicals, Incorporated, Mitsui Toatsu Kagaku Kabushiki Kaisha, Mitsui Toatsu Kagaki Kabushiki Kaisha. Active years: 1981-1994.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tatsuro Yokoyama. Retrieved from https://idiyas.com/inventor/tatsuro-yokoyama

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11

% Patents Active = 100.0

Average Co-Inventor Count = 7.3

ph-index = 4

Forward Citations = 33(Granted Patents)

Location History:

Yokohama, JP (1981 - 1991)
Mobara, JP (1992 - 1994)

Company Filing History:

7 out of 1,379

Mitsui Toatsu Chemicals, Incorporated

patents

2 out of 7

Mitsui Toatsu Kagaku Kabushiki Kaisha

patents

1 out of 1

Mitsui Toatsu Kagaki Kabushiki Kaisha

patent

4. 1 out of 1

Mitsui Toatsu Kaguku Kabushiki Kaisha

patent

Years Active: 1981-1994

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 5332739 - Pyrimidinedione derivatives and antiarrhythmic agents containing same (1994-07-26),

2. 5114941 - Pyrimidinedione derivative compounds, method for preparing same, and (1992-05-19),

3. 5008267 - Pyrimidinedione compounds, method of producing the same and (1991-04-16),

4. 4868292 - Preparation of monosialoganglioside (1989-09-19),

5. 4532137 - 2-Thiazolamine derivatives, process for preparing same, and (1985-07-30),

6. 4524147 - Uracil derivatives, process for preparing same, and pharmaceutical (1985-06-18),

7. 4511574 - N-(4-Phenyl-2-thiazolyl)carbamate derivatives (1985-04-16),

8. 4501750 - Thiazole compounds, a process for preparing same and a pharmaceutical (1985-02-26),

9. 4490393 - Thiazolylurea derivatives, a process for preparing same and a (1984-12-25),

10. 4473577 - 2-Thiazolamine derivatives, process for preparing same, and (1984-09-25),

11. 4256885 - Process for the preparation of 1-(2-tetrahydrofuryl)-5-fluorouracil (1981-03-17),

Title: Innovations of Tatsuro Yokoyama

Introduction

Tatsuro Yokoyama is a prominent inventor based in Yokohama, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of antiarrhythmic agents. With a total of 11 patents to his name, Yokoyama's work has had a substantial impact on medical treatments for cardiac arrhythmias.

Latest Patents

Yokoyama's latest patents include innovative pyrimidinedione derivatives that serve as antiarrhythmic agents. One of his notable inventions involves pyrimidinedione derivatives characterized by a specific formula, where R¹ and R² are linked to form an alkylene chain, creating a heterocyclic structure. These compounds are designed to treat cardiac arrhythmias effectively. Another patent focuses on a pyrimidinedione derivative compound that features a 4-oxobenzopyran ring group linked to a pyrimidinedione part through an alkyl chain containing nitrogen and oxygen. This derivative also aims to provide medical treatment for cardiac arrhythmias.

Career Highlights

Throughout his career, Tatsuro Yokoyama has worked with notable companies such as Mitsui Toatsu Chemicals, Incorporated and Mitsui Toatsu Kagaku Kabushiki Kaisha. His experience in these organizations has contributed to his expertise in the field of chemical innovations.

Collaborations

Yokoyama has collaborated with esteemed colleagues, including Isao Sakano and Yutaka Okazaki. These partnerships have fostered a collaborative environment that has led to significant advancements in their respective fields.

Conclusion

Tatsuro Yokoyama's contributions to the field of medicinal chemistry, particularly through his innovative patents, have made a lasting impact on the treatment of cardiac arrhythmias. His work continues to inspire future innovations in the medical field.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]